The concern of generic rivalry has repeatedly loomed above copyright’s blockbuster drug, Sildenafil, raising questions about the prospects of connected medicinal stakes. While first periods saw substantial profits, the exclusivity lapse has created the path for discounted copies, likely diminishing profitability and presenting a significant dange